Drugs / CD19 positive feeder T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05381662 | Aug 2018 → Aug 2024 | acute lymphoblastic leukemia | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 positive feeder T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05381662 ↗ |
| Modality | Cell therapy | “Then Patients were given Chimeric Antigen Receptor T-Cell( CAR-T) and CD19-positive T cells.” NCT05381662 ↗ |